PoreWise One finding · Human trial · 2026
Study title
Efficacy and Tolerability of 0.2% Thiamidol Cream for Facial Hyperpigmentation: A Randomized, Double-Blind, and Vehicle-Controlled Study
- Kind of evidence
- Human trial 2026 · 200 people · adults with facial hyperpigmentation (196 completed) · PMID 41566113
- Measured outcome
- Skin effect
- Year
- 2026
- Who was studied
- 200 adults with facial hyperpigmentation (196 completed)
- Sample size
- 200
- Measured outcome
- In 200 people with facial hyperpigmentation, a 0.2% Thiamidol cream reduced mMASI scores by 36.1% at week 12 versus 16.1% with the vehicle cream (all time points P < 0.001).
- Certainty
- High
- Who was measured
- Adults with facial hyperpigmentation applying the cream for 12 weeks, assessed by physician-blinded mMASI and standardised photography.
- Study limits
- Similar between-group difference in freckles or solar lentigines, patient global assessment, or digital colour analysis.
Where it comes from
- Efficacy and Tolerability of 0.2% Thiamidol Cream for Facial Hyperpigmentation: A Randomized, Double-Blind, and Vehicle-Controlled Study
Published by Dermatology and Therapy (Lekhavat C, et al.) · Last checked 2026-11-10
Skin concerns studied
Other findings on the same ingredient or concern
- Skin effectA Novel Dermocosmetic Routine Containing Vitamin B3 and 2-Mercaptonicotinyl Glycine Significantly Improves Melasma After 3 Months of Daily Use
In 91 women with melasma, a skincare routine containing vitamin B3 (niacinamide) and 2-mercaptonicotinyl glycine significantly reduced MASI after 3 months, with roughly 38-41% reduction by 6 months.
Human trial · 2025 · 91 people · women with melasma · Women aged about 44 with melasma, phototypes III-IV, using the routine twice daily with daily SPF50+ sunscreen. · A clinically relevant difference favoured Kligman's triple combination in the first 3 months; industry-funded; skin radiance and fine wrinkles also improved.